Theriva Biologics DSMC recommends advancing SYN-004 trial to Cohort 3 after positive Cohort 2 safety data

Theriva Biologics, Inc.

DSMC reviewed safety and PK data from Cohort 2 (19 patients) and recommended study proceed to Cohort 3 using cefepime.
No SAEs or AEs determined related to study drug; 15 SAEs reported among 10 patients typical for allo-HCT.
No patient blood samples positive for SYN-004 at any timepoint; piperacillin PK as expected.
Company pursuing additional funding to enable Cohort 3 conduct; Phase 1b/2a trial remains blinded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.